Therapeutic Efficacy Comparison of Five Major EGFR-TKIs in Advanced EGFR-Positive Non–Small Cell Lung Cancer: A Network Meta-Analysis Based on Head-To-Head Trials

Research paper by Yaxiong Zhang, Zhonghan Zhang, Xiaodan Huang, Shiyang Kang, Gang Chen, Manli Wu, Siyu Miao, Yan Huang, Hongyun Zhao, Li Zhang

Indexed on: 28 Oct '16Published on: 27 Oct '16Published in: Clinical Lung Cancer


Five major first and second generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, icotinib, afatinib, and dacomitinib, are currently optional for advanced non-small-cell lung cancer (NSCLC) patients who harbor EGFR mutations. However, there was no head-to-head-based network meta-analysis among all the TKIs in EGFR-mutated populations.

Figure 10.1016/j.cllc.2016.09.006.0.jpg
Figure 10.1016/j.cllc.2016.09.006.1.jpg
Figure 10.1016/j.cllc.2016.09.006.2.jpg